|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dao F, Schlappe BA, Tseng J, Lester J,
Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan
BY, et al: Characteristics of 10-year survivors of high-grade
serous ovarian carcinoma. Gynecol Oncol. 141:260–263. 2016.
View Article : Google Scholar
|
|
3
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian Cancer Statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garziera M, Cecchin E, Giorda G, Sorio R,
Scalone S, De Mattia E, Roncato R, Gagno S, Poletto E, Romanato L,
et al: Clonal evolution of TP53 c.375+1G > A mutation in pre-
and post-neo-adjuvant chemotherapy (NACT) tumor samples in
high-grade serous ovarian cancer (HGSOC). Cells. 8:11862019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leary A, Tan D and Ledermann J: Immune
checkpoint inhibitors in ovarian cancer: Where do we stand? Ther
Adv Med Oncol. 13:175883592110398992021. View Article : Google Scholar
|
|
6
|
Hamanishi J, Mandai M, Ikeda T, Minami M,
Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S,
et al: Safety and antitumor activity of Anti-PD-1 antibody,
nivolumab, in patients with platinum-resistant ovarian cancer. J
Clin Oncol. 33:4015–4022. 2015. View Article : Google Scholar
|
|
7
|
Ji RR, Chasalow SD, Wang L, Hamid O,
Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M,
Siemers NO, et al: An immune-active tumor microenvironment favors
clinical response to ipilimumab. Cancer Immunol Immunother.
61:1019–1031. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pautu JL and Kumar L: Intratumoral T cells
and survival in epithelial ovarian cancer. Natl Med J India.
16:150–151. 2003.
|
|
9
|
Ovarian Tumor Tissue Analysis (OTTA)
Consortium, . Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W,
Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, et al:
Dose-Response association of CD8+ Tumor-Infiltrating lymphocytes
and survival time in high-grade serous ovarian cancer. JAMA Oncol.
3:e1732902017. View Article : Google Scholar
|
|
10
|
Kaplan MH: STAT4-A critical regulator of
inflammation in vivo. Immunol Res. 31:231–241. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thierfelder WE, Van Deursen JM, Yamamoto
K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA,
Doherty PC, Grosveld GC and Ihle JN: Requirement for Stat4 in
interleukin-12-mediated responses of natural killer and T cells.
Nature. 382:171–174. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuroda E, Kito T and Yamashita U: Reduced
expression of STAT4 and IFN-gamma in macrophages from BALB/c mice.
J Immunol. 168:5477–5482. 2002. View Article : Google Scholar
|
|
13
|
Bacon CM, Petricoini EF III, Ortaldo JR,
Rees RC, Larner AC, Johnston JA and O'Shea JJ: Interleukin 12
induces tyrosine phosphorylation and activation of STAT4 in human
lymphocytes. Proc Natl Acad Sci USA. 92:7307–7311. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang G, Chen JH, Qiang Y, Wang DZ and Chen
Z: Decreased STAT4 indicates poor prognosis and enhanced cell
proliferation in hepatocellular carcinoma. World J Gastroenterol.
21:3983–3993. 2015. View Article : Google Scholar
|
|
15
|
Li S, Sheng B, Zhao M, Shen Q, Zhu H and
Zhu X: The prognostic values of signal transducers activators of
transcription family in ovarian cancer. Biosci Rep.
37:BSR201706502017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang S and Yu L, Shi W, Li X and Yu L:
Prognostic roles of signal transducers and activators of
transcription family in human breast cancer. Biosci Rep.
38:BSR201711752018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harlin H, Meng Y, Peterson AC, Zha Y,
Tretiakova M, Slingluff C, McKee M and Gajewski TF: Chemokine
expression in melanoma metastases associated with CD8+ T-cell
recruitment. Cancer Res. 69:3077–3085. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Spranger S, Bao R and Gajewski TF:
Melanoma-intrinsic β-catenin signalling prevents anti-tumour
immunity. Nature. 523:231–235. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sanchez-Paulete AR, Cueto FJ,
Martínez-López M, Labiano S, Morales-Kastresana A, Rodríguez-Ruiz
ME, Jure-Kunkel M, Azpilikueta A, Aznar MA, Quetglas JI, et al:
Cancer immunotherapy with immunomodulatory Anti-CD137 and Anti-PD-1
monoclonal antibodies requires BATF3-Dependent dendritic cells.
Cancer Discov. 6:71–79. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zsiros E, Duttagupta P, Dangaj D, Li H,
Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, et
al: The ovarian cancer chemokine landscape is conducive to homing
of Vaccine-Primed and CD3/CD28-Costimulated T cells prepared for
adoptive therapy. Clin Cancer Res. 21:2840–2850. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dangaj D, Bruand M, Grimm AJ, Ronet C,
Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL,
Benencia F, et al: Cooperation between constitutive and inducible
chemokines enables T cell engraftment and immune attack in solid
tumors. Cancer Cell. 35:885–900.e10. 2019. View Article : Google Scholar
|
|
22
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An Integrated TCGA Pan-cancer clinical data resource to
drive High-Quality survival outcome analytics. Cell.
173:400–416.e11. 2018. View Article : Google Scholar
|
|
23
|
Konecny GE, Wang C, Hamidi H, Winterhoff
B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, et al:
Prognostic and therapeutic relevance of molecular subtypes in
high-grade serous ovarian cancer. J Natl Cancer Inst.
106:dju2492014. View Article : Google Scholar
|
|
24
|
Yoshihara K, Tsunoda T, Shigemizu D,
Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami
Y, Okamoto A, et al: High-Risk ovarian cancer based on 126-Gene
expression signature is uniquely characterized by downregulation of
antigen presentation pathway. Clin Cancer Res. 18:1374–1385. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ramaswamy V, Remke M, Bouffet E, Faria CC,
Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, et al:
Recurrence patterns across medulloblastoma subgroups: An integrated
clinical and molecular analysis. Lancet Oncol. 14:1200–1207. 2013.
View Article : Google Scholar
|
|
26
|
Hill RM, Kuijper S, Lindsey JC, Petrie K,
Schwalbe EC, Barker K, Boult JK, Williamson D, Ahmad Z, Hallsworth
A, et al: Combined MYC and P53 defects emerge at medulloblastoma
relapse and define rapidly progressive, therapeutically targetable
disease. Cancer Cell. 27:72–84. 2015. View Article : Google Scholar
|
|
27
|
Sun Y, Wu L, Zhong Y, Hou Y, Wang Z, Zhang
Z, Xie J, Wang C, Chen D, Huang Y, et al: Single-cell landscape of
the ecosystem in early-relapse hepatocellular carcinoma. Cell.
184:404–421.e16. 2021. View Article : Google Scholar
|
|
28
|
Becht E, Giraldo NA, Lacroix L, Buttard B,
Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman
C, Fridman WH and de Reyniès A: Estimating the population abundance
of tissue-infiltrating immune and stromal cell populations using
gene expression. Genome Biol. 17:2182016. View Article : Google Scholar
|
|
29
|
Finotello F, Mayer C, Plattner C,
Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W,
Wilflingseder D, et al: Molecular and pharmacological modulators of
the tumor immune contexture revealed by deconvolution of RNA-seq
data. Genome Med. 11:342019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Szklarczyk D, Gable AL, Lyon D, Junge A,
Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork
P, et al: STRING v11: Protein-protein association networks with
increased coverage, supporting functional discovery in genome-wide
experimental datasets. Nucleic Acids Res. 47:D607–D613. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Azim HA Jr, Peccatori FA, Brohée S,
Branstetter D, Loi S, Viale G, Piccart M, Dougall WC, Pruneri G and
Sotiriou C: RANK-ligand (RANKL) expression in young breast cancer
patients and during pregnancy. Breast Cancer Res. 17:242015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(T)(−Delta Delta C) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ling S, Pang J, Yu J, Wang R, Liu L, Ma Y,
Zhang Y, Jin N and Wang S: Preparation and identification of
monoclonal antibody against fumonisin B-(1) and development of
detection by Ic-ELISA. Toxicon. 80:64–72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jones CC, Mercaldo SF, Blume JD, Wenzlaff
AS, Schwartz AG, Chen H, Deppen SA, Bush WS, Crawford DC, Chanock
SJ, et al: Racial disparities in lung cancer survival: The
contribution of stage, treatment, and ancestry. J Thorac Oncol.
13:1464–1473. 2018. View Article : Google Scholar
|
|
36
|
Ju YJ, Lee SW, Kye YC, Lee GW, Kim HO, Yun
CH and Cho JH: Self-reactivity controls functional diversity of
naive CD8+ T cells by co-opting tonic type I interferon.
Nat Commun. 12:60592021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Burgueno-Bucio E, Mier-Aguilar CA and
Soldevila G: The multiple faces of CD5. J Leukoc Biol. 105:891–904.
2019. View Article : Google Scholar
|
|
38
|
Gordiienko I, Shlapatska L, Kovalevska L
and Sidorenko SP: SLAMF1/CD150 in hematologic malignancies: Silent
marker or active player? Clin Immunol. 204:14–22. 2019. View Article : Google Scholar
|
|
39
|
Yang C, Mai H, Peng J, Zhou B, Hou J and
Jiang D: STAT4: An immunoregulator contributing to diverse human
diseases. Int J Biol Sci. 16:1575–1585. 2020. View Article : Google Scholar
|
|
40
|
Yatim N, Cullen S and Albert ML: Dying
cells actively regulate adaptive immune responses. Nat Rev Immunol.
17:262–275. 2017. View Article : Google Scholar
|
|
41
|
Sturm G, Finotello F, Petitprez F, Zhang
JD, Baumbach J, Fridman WH, List M and Aneichyk T: Comprehensive
evaluation of transcriptome-based cell-type quantification methods
for immuno-oncology. Bioinformatics. 35:i436–i445. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nishi M, Batsaikhan BE, Yoshikawa K,
Higashijima J, Tokunaga T, Takasu C, Kashihara H, Ishikawa D and
Shimada M: High STAT4 expression indicates better disease-free
survival in patients with gastric cancer. Anticancer Res.
37:6723–6729. 2017.PubMed/NCBI
|
|
43
|
Wubetu GY, Utsunomiya T, Ishikawa D,
Yamada S, Ikemoto T, Morine Y, Iwahashi S, Saito Y, Arakawa Y,
Imura S, et al: High STAT4 expression is a better prognostic
indicator in patients with hepatocellular carcinoma after
hepatectomy. Ann Surg Oncol. 21 (Suppl 4):S721–S728. 2014.
View Article : Google Scholar
|
|
44
|
Pasquier J, Gosset M, Geyl C,
Hoarau-Véchot J, Chevrot A, Pocard M, Mirshahi M, Lis R, Rafii A
and Touboul C: CCL2/CCL5 secreted by the stroma induce IL-6/PYK2
dependent chemoresistance in ovarian cancer. Mol Cancer. 17:472018.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xu H, Zhao J, Li J, Zhu Z, Cui Z, Liu R,
Lu R, Yao Z and Xu Q: Cancer associated fibroblast-derived CCL5
promotes hepatocellular carcinoma metastasis through activating
HIF1 α/ZEB1 axis. Cell Death Dis. 13:4782022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li H, Chiappinelli KB, Guzzetta AA,
Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM,
Azad NS, et al: Immune regulation by low doses of the DNA
methyltransferase inhibitor 5-azacitidine in common human
epithelial cancers. Oncotarget. 5:587–598. 2014. View Article : Google Scholar
|
|
47
|
Topper MJ, Vaz M, Chiappinelli KB,
DeStefano Shields CE, Niknafs N, Yen RC, Wenzel A, Hicks J, Ballew
M, Stone M, et al: Epigenetic therapy Ties MYC depletion to
reversing immune evasion and treating lung cancer. Cell.
171:1284–1300.e21. 2017. View Article : Google Scholar
|
